AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04668105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High volume nordic hamstring exercise
Description: To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
Study NCT04668105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low volume nordic hamstring exercise
Description: To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
Study NCT01228409 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acitretin 17.5 mg/day
Description: lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
Study NCT04043065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver-enriched antimicrobial peptide 2
Description: Infusion of LEAP-2 during a 180 min grated glucose infusion.
Study NCT04043065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 1
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 110 mg/m2 on day 3
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1200 mg/m2 on day 3
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (maximum 2 mg) on day 3
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2 from day 1 to 5
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor
Description: (G-CSF 5 μg/Kg/day) from day 5 to day 11
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 8 mg/m2 for 3-day
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine ARA-C
Description: 2 g/m2/12 hours for six doses in 3-hour infusion
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg/m2/12 hours before ARA-C administration
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine BCNU
Description: 300 mg/m2 on day -7
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/12 hours
Study NCT00556127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 on day -2
Study NCT00556127 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Involved Field Radiotherapy (IF-RT)
Study NCT00556127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC reinfusion
Description: ASCT
Study NCT02753842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms
Description: Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.
Study NCT02423902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: Approximately 1.0x10\^12 viral particles (vp) per injection
Study NCT02423902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veledimex
Description: 7 oral doses of veledimex
Study NCT00804661 — intervention group
Intervention type: DEVICE
Intervention: SENTEC device
Description: Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
Study NCT01075581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrin (Intranasal injection)
Description: A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
Study NCT01075581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin (Topical administration)
Description: An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
Study NCT02270970 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: belimumab
Description: belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
Study NCT00048581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Vials, intravenous (IV), \~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
Study NCT00048581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
Study NCT00048581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Vials, IV, \~10mg/kg abatacept, every 4 weeks, 5.5 years
Study NCT03500692 — intervention group
Intervention type: DEVICE
Intervention: MitraClip NT System
Description: Percutaneous mitral valve repair using MitraClip NT System
Study NCT01459328 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~* Injected Leucovorin 20 mg/m2/day for 5 days
Study NCT01459328 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conventional long course chemo-radiation:~* Radiation 50Gy in 25 daily fractions over 5 weeks~* Bolus 5 Fluorouracil 350mg/m2/d for 5 days~* Injected Leucovorin 20mg in both the first and last (5th) week of radiation~* Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks.
Study NCT04666909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP > 135 mm Hg or DBP > 85 mmHg (based on the average of 3 BP readings); or average SBP > 130 mm Hg or DBP > 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN.
Study NCT01279525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multifactorial
Description: individual advice, information leaflet, physical exercise workshop and home visits
Study NCT02154321 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
Study NCT02780570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Volume Plasma Exchange
Description: Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
Study NCT02051309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
Study NCT02051309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03174756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous Acid
Description: Mouthwashes of antiplaque agents
Study NCT03174756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
Study NCT03174756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water as placebo
Study NCT03423225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF®
Description: Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks.
Study NCT01371409 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: continuous theta burst stimulation
Description: 80% active motor threshold, 600 pulses
Study NCT01371409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: 80% active motor threshold, 600 pulses
Study NCT01234103 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits
Description: Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
Study NCT01234103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits
Description: Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
Study NCT00802100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Daily tablets of 10 to 30 mg
Study NCT00802100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perphenazine
Description: Daily tablets of 8 to 24 mg
Study NCT00802100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Daily tablets of 10 to 30 mg
Study NCT00802100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Daily tablets of 850 to 2550 mg
Study NCT00802100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily tablets of 20 to 40 mg
Study NCT00802100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine
Description: Daily tablets of 1 to 2 mg
Study NCT03171155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XPro System
Description: Implantation of the XPro System
Study NCT04112082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Neurofeedback
Description: Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
Study NCT04112082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
Study NCT02613156 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic resection
Description: The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson \& Johnson, USA), a laparoscopic linear cutter stapler (Johnson \& Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
Study NCT04137679 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
Study NCT04137679 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
Study NCT04137679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiochemotherapy followed by surgery
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
Study NCT04137679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Radiochemotherapy followed by surgery
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
Study NCT02029105 — intervention group
Intervention type: BIOLOGICAL
Intervention: Mesothelin, hyaluronan, osteopontin, syndecan-1
Description: We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
Study NCT00912288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon 20 mg po TID
Description: Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
Study NCT00912288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo po TID
Description: Placebo (matched to Dimebon) po for 26 weeks
Study NCT00611819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg interferon + Ribavirin
Description: Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
Study NCT00611819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg interferon + Ribavirin
Description: Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
Study NCT01570699 — intervention group
Intervention type: GENETIC
Intervention: COMT polymorphism
Description: The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
Study NCT01311804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parecoxib sodium
Description: periarticular parecoxib sodium injection will be given during total knee arthroplasty
Study NCT01311804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib sodium
Description: intravenous parecoxib sodium during total knee arthroplasty
Study NCT01703832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurexan®
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Study NCT04168788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test for genetic analysis
Description: Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
Study NCT01317927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat, Warfarin
Description: 1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
Study NCT01165671 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
Study NCT01165671 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Radiotherapy
Description: Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
Study NCT02830022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological explorations
Study NCT02268032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA 2.2 g in vaginal ring
Study NCT02268032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Another Androgenic Agent (VRaA)
Description: Testosterone 35 mg in vaginal ring
Study NCT02268032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed combination of 2 androgenic agents (VR2A)
Description: DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
Study NCT01050803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDSME group
Description: In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
Study NCT01050803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FDSME
Description: In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
Study NCT00912353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Single Oral
Study NCT00912353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Oral
Study NCT01424644 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Description: All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®.